T

Telix Pharmaceuticals
TLX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
A$8.38B
EV
A$8.25B
Shares Outstanding
350.39M
Beta
2.41

Wall Street View

Analyst Rating
BUY
Analyst Target Price
A$32.05
P/E 2025E
55.00x
P/Revenue 2025E
6.56x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Telix Pharmaceuticals Limited

gainify

T

Telix Pharmaceuticals Limited

TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United Stat...

Sector

Healthcare

Industry

Biotechnology

CEO

Behrenbruch, Christian

Employees

423

IPO Date

2017-11-14

Headquarters

55 Flemington Road, Suite 401, North Melbourne, Victoria, 3051, Australia

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.